1Olson KB, Hall TC, Horton J, et al. Thalidomide ( N - phthaloylglu tamimide) in the trealment of advanced cancer [ J ]. Clin Pharmacol Ther, 1965,40:292 - 297.
2Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloraa [ J ]. N Engl J Med, 1999, 341(21) : 1565 - 1571.
3Barlogie B, Zangari M, Spencer T, et al. Thalidomide in the management of multiple myeloma [ J ]. Semin Heraatol, 2001,38 ( 3 ) : 250 -259.
4Barlogie B, Desikan R, Eddlemon P, et al. Extended sttrvival in advanced and refractory multiple myelorrm after single - agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients[J]. Blood,2001,98(2) :492 - 494.
5Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multipie myeloma[ J]. Blood,2001,98( 1 ) :210 - 216.
6Hideshima T, Chauhan D, Shirm Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma ceils to conventional therapy[J]. Blood,2000,96(9) :2943 - 2950.
7Juliusson G, Celsing F, Tursson 1, et al. Frequent good pamal remission from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma[ J ]. Br J Haematol,2000, 109(1):89-96.
